Unlocking the Potential of Ribosomal Protein S26 Pseudogene 10 as a Drug Target or Biomarker

Target Name: RPS26P10

NCBI ID: G401470

RPS26P10

Other Name(s): ribosomal protein S26 pseudogene 10 | RPS26_16_925 | Ribosomal protein S26 pseudogene 10

Unlocking the Potential of Ribosomal Protein S26 Pseudogene 10 as a Drug Target or Biomarker

Introduction

Ribosomal protein S26 (RPS26) is a key protein that plays a critical role in the regulation of gene expression and cell signaling. The S26 protein is composed of 26 amino acid residues and is expressed in various cell types. One of the unique features of the S26 protein is its ability to interact with small molecules, including drugs, leading to its potential as a drug target or biomarker. In this article, we will explore the S26 protein and its potential as a drug target or biomarker.

The S26 Protein: Structure and Function

The S26 protein is a member of the small GTPase-activating protein (GAP) family, which includes proteins that regulate the activity of GTPases, including cyclic ADP-ribose synthases (CARs) and protein kinases (PK)s. The S26 protein is characterized by a unique N-terminal domain that includes a nucleotide-binding oligomerization (NBO) domain and a leucine-rich repeat (LRR) domain.

The NBO domain is a unique feature that allows the S26 protein to interact with small molecules, including drugs. The NBO domain is composed of a nucleotide-binding oligomerization (NBO) domain and a C-terminal domain that includes a conserved alpha-helix Structure. The NBO domain functions as a binding site for small molecules, including drugs, leading to its potential as a drug target.

The LRR domain is a structural feature that is involved in the regulation of protein stability and function. The LRR domain is composed of a unique farnesylated cysteine 鈥嬧?媟esidue, which is involved in the regulation of protein stability and functions as a targets for small molecules, including drugs.

The S26 Protein as a Drug Target

The S26 protein has been identified as a potential drug target due to its unique structure and function. The NBO domain and LRR domain of the S26 protein make it an attractive target for small molecules, including drugs.

The NBO domain of the S26 protein is known to interact with small molecules, including drugs. The S26 protein has been shown to interact with various small molecules, including inhibitors of the protein kinase (PK) 1/2, which is involved in cell signaling . Additionally, the S26 protein has been shown to interact with small molecules that are known to be potent inhibitors of the S26 protein itself, indicating that it may be a good target for drugs that are designed to inhibit the activity of the S26 protein.

The LRR domain of the S26 protein is also involved in the regulation of protein stability and function, making it another potential drug target. The S26 protein has been shown to interact with small molecules that are known to be potent inhibitors of the LRR domain, indicating that it may be a good target for drugs that are designed to inhibit the activity of the LRR domain.

The S26 Protein as a Biomarker

The S26 protein has also been identified as a potential biomarker for various diseases, including cancer. Additionally, the S26 protein has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancers. to be involved in cell signaling, which may be a potential biomarker for various diseases.

Conclusion

In conclusion, the S26 protein has a unique structure and function that makes it an attractive target for small molecules, including drugs. The NBO domain and LRR domain of the S26 protein have been shown to interact with small molecules, including drugs, indicating that it may be a good target for drugs that are designed to inhibit the activity of the S26 protein. Additionally, the S26 protein has

Protein Name: Ribosomal Protein S26 Pseudogene 10

The "RPS26P10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS26P10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets